Daxor Corporation reports developments tied to blood volume measurement technology, including commercialization of its FDA-cleared Blood Volume Analysis diagnostics and the BVA-100 Blood Volume Analyzer. Company news commonly covers clinical data, cardiology and critical-care use cases, new customer programs, conference presentations, and product updates for rapid, portable BVA systems.
Daxor also issues updates on financial results, shareholder communications, capital actions, and market expansion for its ezBVA Lab workflow and related diagnostic services. Its coverage centers on precision fluid management, heart failure, ICU care, and adoption of direct blood, plasma, and red-cell volume measurement in clinical settings.
Daxor Corporation (NYSE: DXR) has announced promising new data from a pilot randomized control trial validating the accuracy of its BVA-100 diagnostic in managing heart failure therapy. The study, conducted at Duke Heart, highlighted a potential reduction in hospital stay by 2.7 days (P0.09) for patients receiving BVA-guided care. The results, presented at the Technology Heart Failure Therapeutics Conference, indicated a significant discrepancy between physician assessments and BVA results. Daxor aims to leverage this data to support larger-scale clinical studies, reinforcing the effectiveness of blood volume analysis in improving heart failure treatment outcomes.
Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement, updated shareholders in a letter dated March 1, 2023, from CEO Michael Feldschuh. The company reported a 36.95% increase in net assets to $28,969,469 with significant progress in commercialization, product development, and clinical outcomes. A notable launch is the next-generation portable blood volume analyzer, validated to be three times faster than the current model. Daxor expects an uptick in revenue from single-use diagnostics kits, projected to increase 59.5% in 2022. Additionally, partnerships with the U.S. Department of Defense and other entities are aimed at enhancing product availability and market penetration.
Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, announced a significant increase in its net asset value (NAV) per share, rising to $6.75 for fiscal 2022, up 36.95% from $5.24 in 2021. The company reported a 20.5% rise in unaudited revenues, driven by a 59.5% increase in sales of its blood volume analysis diagnostic systems. With new partnerships and contracts, including with the U.S. DOD and NIH, Daxor plans to launch its next-generation system in 2023. Upcoming clinical trials are expected to further validate the efficacy of its technology.
Daxor Corporation (Nasdaq: DXR) will report its financial results for the year ending December 31, 2022 on March 1, 2023, after market close. The company will also hold a conference call on March 2, 2023, at 9 AM EST, where President Michael Feldschuh and CFO Robert Michel will discuss the results and ongoing corporate initiatives. Daxor, a leader in blood volume measurement technology, aims to enhance healthcare with its FDA-cleared BVA-100 diagnostic test, which has significantly impacted patient outcomes in heart failure and critical care. The company is conducting multicenter trials supported by the NIH, focusing on COVID-19 and heart failure treatment.
Daxor Corporation (Nasdaq: DXR) announced the appointment of Linda Cooper as Vice President of Project Management, effective February 17, 2023. With over 30 years of experience in the medical device industry, Cooper will lead development projects, including next-generation systems and oversee operations at the Oak Ridge facility. Previously, she held senior roles at OsteoCentric Technologies and Integra LifeSciences, managing product launches from design to regulatory clearance. Cooper expressed enthusiasm for optimizing procedures and planning for future growth as the company prepares for its significant technology launch in 20 years.
Daxor Corporation (Nasdaq: DXR) has become a corporate member of the Heart Failure Society of America (HFSA) to enhance engagement with heart failure leaders. This collaboration aims to improve patient outcomes as heart failure affects over 6 million Americans, with nearly 1 million deaths annually. CEO Michael Feldschuh highlighted the opportunity to advance their BVA-100 technology for better product adoption. The membership allows access to HFSA leadership and year-round brand promotion, with goals to expand their user base and products in 2023.
Daxor Corporation (Nasdaq: DXR) announced its participation in the 2023 Critical Care Congress by the Society for Critical Care Medicine, scheduled from January 21 to 24 in San Francisco.
CEO Michael Feldschuh emphasized the congress as a significant opportunity to expand business, focusing on the critical care market's demand for volume management solutions. Daxor's BVA-100® (Blood Volume Analyzer) has shown promising results in improving patient outcomes, including a 66% reduction in mortality in surgical ICU settings. The company aims to enhance healthcare through optimal fluid management and has conducted over 60,000 tests at leading hospitals.
Daxor Corporation (Nasdaq: DXR) announces a groundbreaking study published in the Journal of Cardiovascular Translational Research. The research highlights the inaccuracy of pressure measures in assessing blood volume in heart failure patients compared to the BVA-100 blood test. Results showed a significant lack of correlation between PADP and total blood volume (TBV) measurements, emphasizing the 98% accuracy of direct volume measurement. The study reinforces the importance of blood volume analysis in improving patient outcomes and management in heart failure, supported by extensive published research.
Daxor Corporation (Nasdaq: DXR) has successfully closed its underwritten public offering, issuing 210,527 shares at $9.50 per share, generating gross proceeds of approximately $2.1 million. The offering was slightly increased by the underwriter's partial exercise of an over-allotment option, which added 10,523 shares. Proceeds will be utilized for working capital, product development, capital expenditures, and potential acquisitions. The offering was conducted under an effective shelf registration statement filed with the SEC.
Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, has priced a public offering of 210,527 shares at $9.50 per share, aiming for gross proceeds of $2.0 million. The offering includes an additional option for underwriters to purchase up to 10,527 extra shares. The net proceeds will be allocated towards working capital, product development, and potential acquisitions. The offering is set to close on November 17, 2022, pending customary conditions.